



Annex Figure 1A. Kaplan-Meier survival estimates by tumour burden (complete dataset)



Number at risk

	0	6	12	18	24	30	36	42	48	54	60
Low	99	88	71	48	37	28	23	20	17	11	10
Moderate	138	111	78	44	33	23	18	13	10	7	5
High	223	180	114	64	50	29	18	10	5	3	2
Very high	277	203	128	78	51	26	18	15	11	6	5


Annex Figure 1B. Kaplan-Meier survival estimates by tumour burden (validation cohort)



Number at risk


Low	17	15	12	9	7
Moderate	22	16	11	4	3
High	33	19	11	6	6
Very high	11	5	3	2	2

Annex Figure 2. Kaplan-Meier curves for the standardised distribution of the residuals of the fitted log-normal AFT model




Residuals have been stratified by the covariates in the model, plus a random variable to demonstrate natural variability. The theoretical distribution of the residues is shown with a thicker line.


Annex Figure 3. Calibration plots for overall survival in the training (AGAMENON-SEOM) cohort



Annex Figure 4A. Somers' Dxy rank correlations for progression-free survival




Annex Figure 4B. Somers' Dxy rank correlations for overall survival



Abbreviations: NLR= neutrophil-to-lymphocyte ratio, HER2= human epidermal growth factor receptor 2, CEA= carcinoembryony antigen, ECOG= Eastern Cooperative Group performance status.

Annex Figure 5. Hazard ratio for overall survival associated with the neutrophil-lymphocyte ratio.



Estimates are derived from the multivariable accelerated failure time model. The nonlinear effect is captured by a restricted cubic spline with three knots. OS= overall survival.

Model formulas for HER2-positive gastric tumors

Alberto Carmona Bayonas

15/07/22

Overall survival

$$\text{Prob}\{T \geq t\} = 1 - \Phi\left(\frac{\log(t) - X\hat{\beta}}{0.8968617}\right) \text{ where}$$

$$X\hat{\beta} =$$

$$\begin{aligned} &4.311043 \\ &-0.2125658\text{rnl}_2 + 0.007033983(\text{rnl}_2 - 1.641729)_+^3 \\ &-0.01002682(\text{rnl}_2 - 3.464815)_+^3 + 0.00299284(\text{rnl}_2 - 7.74956)_+^3 \\ &-0.1018133[1] - 0.5737084[2] \\ &-0.2836102[2] - 0.1687748 \text{Her}_2 \\ &-0.2321276[2] - 0.3280515[3] \\ &-0.1830526[3] - 0.4491247[4] - 0.5440473[5] \end{aligned}$$

and $[c] = 1$ if subject is in group c , 0 otherwise; $(x)_+ = x$ if $x > 0$, 0 otherwise

Progression-free survival

$$\text{Prob}\{T \geq t\} = 1 - \Phi\left(\frac{\log(t) - X\hat{\beta}}{0.9310029}\right) \text{ where}$$

$$\begin{aligned}
X\hat{\beta} = & \\
& 3.652705 \\
& -0.1739737\text{rnl}_2 + 0.005849147(\text{rnl}_2 - 1.641729)_+^3 \\
& -0.00833786(\text{rnl}_2 - 3.464815)_+^3 + 0.002488713(\text{rnl}_2 - 7.74956)_+^3 \\
& -0.02141783[1] - 0.4300332[2] \\
& -0.3035236[2] - 0.2728151 \text{Her}_2 \\
& -0.1578525[2] - 0.2193954[3] \\
& -0.09823317[3] - 0.4553912[4] - 0.4728883[5]
\end{aligned}$$

and $[c] = 1$ if subject is in group c , 0 otherwise; $(x)_+ = x$ if $x > 0$, 0 otherwise